Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
January 09 2024 - 4:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced its support for the
American Society of Clinical Oncology (ASCO)—Society of Surgical
Oncology (SSO) guideline for germline testing in patients with
breast cancer.
The new guideline offers multi-pronged, evidence-based clinical
practice recommendations. Among the guidance includes:
- All patients with a current or previous diagnosis of invasive
breast cancer ≤ 65 years should be offered BRCA1/2
testing.
- All patients with a current or previous diagnosis of invasive
breast cancer > 65 years should be offered BRCA1/2 testing if
personal or family history suggests the possibility of a pathogenic
variant or are candidates for a PARP inhibitor therapy.
- Testing for high and moderate penetrance breast cancer genes
beyond BRCA1/2 can inform medical therapy, influence surgical
decision-making, refine risk estimates for future cancers, inform
family members, and should be offered to appropriate
patients.
- Patients undergoing genetic testing should be given sufficient
information before testing to provide informed consent. Formal
genetic counseling sessions may not always be possible, and several
alternative approaches exist.
“ASCO-SSO’s guideline update is an important step forward in
advancing the use of genomics in clinical care for patients with
breast cancer,” said Shelly Cummings, Vice President of Oncology
Medical Affairs, Myriad Genetics. “The latest clinical practice
recommendations expand access to genetic testing and limit barriers
to care, both of which closely align with Myriad’s commitment to
advance the health and well-being for all patients and their family
members.”
Myriad’s germline test, MyRisk® Hereditary Cancer Test,
analyzes 48 genes linked to 11 cancer types including breast
cancer. Germline testing can help guide more personalized treatment
decisions, including targeted therapies and surgical
techniques.
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including the
statement that the latest clinical practice recommendations expand
access to genetic testing and limit barriers to care. These
“forward-looking statements” are management’s expectations of
future events as of the date hereof and are subject to known and
unknown risks and uncertainties that could cause actual results,
conditions, and events to differ materially and adversely from
those anticipated. Such factors include those risks described in
the company’s filings with the U.S. Securities and Exchange
Commission, including the company’s Annual Report on Form 10-K
filed on March 1, 2023, as well as any updates to those risk
factors filed from time to time in the company’s Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K. Myriad is not under
any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024